Nasdaq · CIK 0001862150
CING Cingulate Inc.
Insider trading from SEC Form 4. Last filing 11 d ago. Close $4.89 on Oct 9, 2026, +47% from the 52-week low and -58% from the high.
Cingulate Inc. (CING) has 38 SEC Form 4 filings on file from 12 insiders, the latest filed on Oct 2, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
5 open-market trades have been scored at CING. The newest: Thomas Jeffrey Hargroves (director) bought $490k of stock on Feb 13, 2026, filed Jun 8, 2026, scored 62 (notable). 5 insiders bought within 14 days of each other around Feb 13, 2026.
CING closed at $4.89 on Oct 9, 2026, 47% above its 52-week low and 58% below its 52-week high.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Cingulate Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 62Notable | Thomas Jeffrey Hargroves director buy | $490k 97,276 shares | first purchase | +80% from low-22% from high | |
| 40Moderate | Matthew Brams EVP and Chief Medical Officer buy | $9,808 1,946 shares | +72% | +131% from low0% from high | |
| 47Moderate | Jennifer L. Callahan SVP and CFO buy | $25k 4,864 shares | +2494% | +131% from low0% from high | |
| 56Moderate | Shane J. Schaffer Chief Executive Officer buy | $34k 6,809 shares | +202% | +131% from low0% from high | |
| 43Moderate | Peter J. Werth director buy | $98k 19,455 shares | +20% | +131% from low0% from high |
Transactions
Every row filed, 50 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | Raul R. Silva EVP and CSO | AGrant or award Stock Option (right to Buy)derivative | +4,293 | $0.00 | $0 | 4,293 | 11 d ago |
| Feb 13, 2026 | Thomas Jeffrey Hargroves director | POpen-market purchase Common Stockindirect: By Hargroves Family Investments, LLC | +97,276 | $5.04 | $490k | 97,468 | Jun 8, 2026 |
| Feb 13, 2026 | Thomas Jeffrey Hargroves director | POpen-market purchase Warrant to Purchase Common Stockderivativeindirect: By Hargroves Family Investments, LLC | +77,821 | $0.10 | $7,782 | 77,821 | Jun 8, 2026 |
| Mar 9, 2026 | Thomas Jeffrey Hargroves director | AGrant or award Stock Option (right to Buy)derivative | +15,000 | $0.00 | $0 | 15,000 | Jun 8, 2026 |
| Mar 31, 2026 | Raul R. Silva EVP and CSO | AGrant or award Stock Option (right to Buy)derivative | +3,422 | $0.00 | $0 | 3 | May 8, 2026 |
| Mar 9, 2026 | Shane J. Schaffer Chief Executive Officer | AGrant or award Common Stock | +6,862 | $0.00 | $0 | 7,035 | Mar 11, 2026 |
| Mar 9, 2026 | Jennifer L. Callahan EVP and CFO | AGrant or award Common Stock | +15,329 | $0.00 | $0 | 20,388 | Mar 11, 2026 |
| Mar 9, 2026 | Raul R. Silva EVP and CSO | AGrant or award Common Stock | +4,526 | $0.00 | $0 | 6,473 | Mar 11, 2026 |
| Mar 9, 2026 | Matthew Brams EVP and Chief Medical Officer | AGrant or award Common Stock | +4,526 | $0.00 | $0 | 9,182 | Mar 11, 2026 |
| Mar 9, 2026 | Nilay Dahyabhai Patel EVP, CLO and CCO | AGrant or award Common Stock | +5,475 | $0.00 | $0 | 5,475 | Mar 11, 2026 |
| Mar 9, 2026 | Nilay Dahyabhai Patel EVP, CLO and CCO | FTax withholding Common Stock | -2,086 | $0.00 | $0 | 3,389 | Mar 11, 2026 |
| Mar 9, 2026 | Jennifer L. Callahan EVP and CFO | FTax withholding Common Stock | -6,427 | $0.00 | $0 | 13,961 | Mar 11, 2026 |
| Mar 9, 2026 | Matthew Brams EVP and Chief Medical Officer | FTax withholding Common Stock | -1,025 | $0.00 | $0 | 8,157 | Mar 11, 2026 |
| Mar 9, 2026 | Shane J. Schaffer Chief Executive Officer | FTax withholding Common Stock | -2,959 | $0.00 | $0 | 4,076 | Mar 11, 2026 |
| Mar 9, 2026 | Raul R. Silva EVP and CSO | FTax withholding Common Stock | -1,828 | $0.00 | $0 | 4,645 | Mar 11, 2026 |
| Feb 6, 2026 | Matthew Brams EVP and Chief Medical Officer | POpen-market purchase Common Stock | +1,946 | $5.04 | $9,808 | 4,656 | Feb 10, 2026 |
| Feb 6, 2026 | Jennifer L. Callahan SVP and CFO | POpen-market purchase Common Stock | +4,864 | $5.04 | $25k | 5,059 | Feb 10, 2026 |
| Feb 6, 2026 | Shane J. Schaffer Chief Executive Officer | POpen-market purchase Common Stockindirect: By Fountainhead Shrugged, LLC | +6,809 | $5.04 | $34k | 10,175 | Feb 10, 2026 |
| Feb 6, 2026 | Peter J. Werth director | POpen-market purchase Common Stockindirect: By Werth Family Investment Associates LLC | +19,455 | $5.04 | $98k | 117,449 | Feb 10, 2026 |
| Feb 6, 2026 | Matthew Brams EVP and Chief Medical Officer | POpen-market purchase Warrant to Purchase Common Stockderivative | +1,556 | $0.10 | $156 | 1,556 | Feb 10, 2026 |
| Feb 6, 2026 | Jennifer L. Callahan SVP and CFO | POpen-market purchase Warrant to Purchase Common Stockderivative | +3,891 | $0.10 | $389 | 3,891 | Feb 10, 2026 |
| Feb 6, 2026 | Shane J. Schaffer Chief Executive Officer | POpen-market purchase Warrant to Purchase Common Stockderivativeindirect: By Fountainhead Shrugged, LLC | +5,447 | $0.10 | $545 | 5,447 | Feb 10, 2026 |
| Feb 6, 2026 | Peter J. Werth director | POpen-market purchase Warrant to Purchase Common Stockderivativeindirect: By Werth Family Investment Associates LLC | +15,564 | $0.10 | $1,556 | 15,564 | Feb 10, 2026 |
| Dec 31, 2025 | Raul R. Silva EVP and CSO | AGrant or award Stock Option (right to Buy)derivative | +6,625 | $0.00 | $0 | 6,625 | Jan 5, 2026 |
| Nov 3, 2025 | Bryan Wade Downey Chief Commercial Officer | AGrant or award Stock Option (right to Buy)derivative | +30,000 | $0.00 | $0 | 30,000 | Nov 10, 2025 |
| Sep 30, 2025 | Raul R. Silva EVP and CSO | AGrant or award Stock Option (right to Buy)derivative | +7,334 | $0.00 | $0 | 7,334 | Nov 10, 2025 |
| Jul 8, 2025 | Nilay Dahyabhai Patel CLO and CCO | AGrant or award Stock Option (right to Buy)derivative | +30,000 | $0.00 | $0 | 30,000 | Jul 10, 2025 |
| Jul 7, 2025 | Raul R. Silva EVP and CSO | AGrant or award Stock Option (right to Buy)derivative | +51,500 | $0.00 | $0 | 51,500 | Jul 9, 2025 |
| Jul 7, 2025 | Matthew Brams EVP and Chief Medical Officer | AGrant or award Stock Option (right to Buy)derivative | +52,500 | $0.00 | $0 | 52,500 | Jul 9, 2025 |
| Jul 7, 2025 | Jennifer L. Callahan SVP and CFO | AGrant or award Stock Option (right to Buy)derivative | +64,500 | $0.00 | $0 | 64,500 | Jul 9, 2025 |
| Jul 7, 2025 | Laurie Myers EVP and COO | AGrant or award Stock Option (right to Buy)derivative | +31,000 | $0.00 | $0 | 31,000 | Jul 9, 2025 |
| Jul 7, 2025 | Shane J. Schaffer Chief Executive Officer | AGrant or award Stock Option (right to Buy)derivative | +199,500 | $0.00 | $0 | 199,500 | Jul 9, 2025 |
| Mar 31, 2025 | Raul R. Silva EVP and CSO | AGrant or award Stock Option (right to Buy)derivative | +1,000 | $0.00 | $0 | 1,000 | Jul 1, 2025 |
| Jun 30, 2025 | Raul R. Silva EVP and CSO | AGrant or award Stock Option (right to Buy)derivative | +1,000 | $0.00 | $0 | 1,000 | Jul 1, 2025 |
| Jun 20, 2025 | Jeffrey S Ervin director | AGrant or award Stock Option (right to Buy)derivative | +15,000 | $0.00 | $0 | 15,000 | Jun 23, 2025 |
| Jun 20, 2025 | Bryan Jay Lawrence director | AGrant or award Stock Option (right to Buy)derivative | +15,000 | $0.00 | $0 | 15,000 | Jun 23, 2025 |
| Jun 20, 2025 | John A Roberts director | AGrant or award Stock Option (right to Buy)derivative | +15,000 | $0.00 | $0 | 15,000 | Jun 23, 2025 |
| Jun 20, 2025 | Peter J. Werth director | AGrant or award Stock Option (right to Buy)derivative | +15,000 | $0.00 | $0 | 15,000 | Jun 23, 2025 |
| Feb 18, 2025 | Matthew Brams EVP and Chief Medical Officer | AGrant or award Stock Option (right to Buy)derivative | +17,630 | $0.00 | $0 | 17,630 | Feb 20, 2025 |
| Feb 18, 2025 | Jennifer L. Callahan SVP and CFO | AGrant or award Stock Option (right to Buy)derivative | +21,140 | $0.00 | $0 | 21,140 | Feb 20, 2025 |
| Feb 18, 2025 | Raul R. Silva EVP and CSO | AGrant or award Stock Option (right to Buy)derivative | +17,630 | $0.00 | $0 | 17,630 | Feb 20, 2025 |
| Feb 18, 2025 | Laurie Myers EVP and COO | AGrant or award Stock Option (right to Buy)derivative | +17,630 | $0.00 | $0 | 17,630 | Feb 20, 2025 |
| Feb 18, 2025 | Shane J. Schaffer Chief Executive Officer | AGrant or award Stock Option (right to Buy)derivative | +70,489 | $0.00 | $0 | 70,489 | Feb 20, 2025 |
| Jan 17, 2025 | Matthew Brams EVP and Chief Medical Officer | AGrant or award Stock Option (right to Buy)derivative | +2,748 | $0.00 | $0 | 2,748 | Jan 22, 2025 |
| Jan 17, 2025 | Jennifer L. Callahan SVP and CFO | AGrant or award Stock Option (right to Buy)derivative | +11,539 | $0.00 | $0 | 11,539 | Jan 22, 2025 |
| Jan 17, 2025 | Shane J. Schaffer Chief Executive Officer | AGrant or award Stock Option (right to Buy)derivative | +27,638 | $0.00 | $0 | 27,638 | Jan 22, 2025 |
| Jan 17, 2025 | Laurie Myers EVP and COO | AGrant or award Stock Option (right to Buy)derivative | +9,319 | $0.00 | $0 | 9,319 | Jan 22, 2025 |
| Jan 17, 2025 | Raul R. Silva EVP and CSO | AGrant or award Stock Option (right to Buy)derivative | +2,748 | $0.00 | $0 | 2,748 | Jan 22, 2025 |
| Dec 31, 2024 | Matthew Brams EVP and Chief Medical Officer | AGrant or award Stock Option (right to Buy)derivative | +1,000 | $0.00 | $0 | 1,000 | Jan 7, 2025 |
| Dec 31, 2024 | Raul R. Silva EVP and CSO | AGrant or award Stock Option (right to Buy)derivative | +1,000 | $0.00 | $0 | 1,000 | Jan 7, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Matthew BramsEVP and Chief Medical Officer
- Jennifer L. CallahanEVP and CFO
- Bryan Wade DowneyChief Commercial Officer
- Jeffrey S Ervindirector, cfo, officer
- Thomas Jeffrey Hargrovesdirector
- Bryan Jay Lawrencedirector
- Laurie MyersEVP and COO
- Nilay Dahyabhai PatelEVP, CLO and CCO
- John A Robertsdirector
- Shane J. SchafferChief Executive Officer
- Raul R. SilvaEVP and CSO
- Peter J. Werthdirector
Questions about CING
Answered from the filings on this page, as of the latest one.
Are insiders buying CING?
No. In the last 90 days no insider at Cingulate Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade CING on the open market?
Thomas Jeffrey Hargroves (director) bought $490k of CING on Feb 13, 2026 and filed the Form 4 on Jun 8, 2026. InsiderTell scored 62 (notable), with 5 insiders on the same side within 14 days.
How many insiders file Form 4 at Cingulate Inc.?
12 people have filed a Form 4 at Cingulate Inc., among them Matthew Brams (EVP and Chief Medical Officer), Jennifer L. Callahan (EVP and CFO), Bryan Wade Downey (Chief Commercial Officer). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.